Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Feb 07, 2024 12:32pm
179 Views
Post# 35867763

RE:RE:Spectral move

RE:RE:Spectral move

The math is correct. Say $5.5 M. 
But I ask what will compel warrant holders to exercise before Dec 2024? 

Also another Baxter tranche ( assuming the option is exercised) needs to be factored into the $ pending. ($5-$10m CAD?) 

Still not convinced they won't pull the trigger on up to another 10 -20 million shares. But at current prices, 10m brings in another $6m or so ( after commissions etc) Hopefully much more post 90 patient milestone hype. 

Bottom-line? Raising $ should not be a concern. With minimal dilution either way. 


MM 

<< Previous
Bullboard Posts
Next >>